English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 24 September 2019, 09:01 HKT/SGT
Share:
    

Source: Eisai
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress

TOKYO, Sept 24, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain, from September 27 to October 1, 2019. The abstracts highlight updates regarding Eisai's in-house discovered LENVIMA (lenvatinib mesylate, the orally available kinase inhibitor, "lenvatinib"), and Halaven (eribulin mesylate, "eribulin", halichondrin class microtubule dynamics inhibitor).

At the ESMO 2019 Congress, there will be an oral presentation of results from the final analysis of the endometrial carcinoma cohort of Study 111/KEYNOTE-146, a Phase Ib/II study evaluating the combination treatment of lenvatinib and Merck & Co., Inc., Kenilworth, NJ., U.S.A.'s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in select solid tumors (Abstract No.: 994O). The combination treatment was the first to be approved in the United States, Australia and Canada under the U.S. Food and Drug Administration's Project Orbis in Sept 2019

A total of 11 poster presentations are scheduled, including one on the updated results of the lenvatinib plus pembrolizumab combination treatment in unresectable hepatocellular carcinoma in study 116/KEYNOTE- 524, a Phase 1b study (Abstract No.: 747P), and the interim analysis evaluating the combination after disease progression after PD-1/PD-L1 immune checkpoint blockade in renal cell carcinoma (RCC) from 111/KEYNOTE-146 RCC cohort (Abstract No.: 1187PD). In addition, the latest data from a Phase I study for an eribulin liposomal formulation in solid tumors (Abstract No.: 348P) will be presented.

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:
Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120


Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Releated News
Nov 13, 2019 15:00 HKT/SGT
エーザイ、人事異動を発表
Nov 5, 2019 10:00 HKT/SGT
エーザイ、EZH2阻害剤タゼメトスタットについて日本以外の地域における売上ロイヤルティ受領の権利をRoyalty Pharmaに譲渡
Nov 5, 2019 09:02 HKT/SGT
Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma
Oct 23, 2019 10:13 HKT/SGT
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
Oct 23, 2019 10:00 HKT/SGT
バイオジェンとエーザイ、アデュカヌマブ 臨床第III相試験で得られた大規模データセットの新たな解析結果に基づき、アルツハイマー病を対象とした新薬承認申請を予定
More news >>
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575